Troubled KV cuts 700 jobs amid suspension

Share this article:
KV Pharmaceutical Company said it is eliminating 700 jobs as part of a cost-cutting program following a suspension of manufacturing and product recalls resulting from an FDA investigation.

The St. Louis-based specialty drug maker did not specify where cuts might fall, but said they would come in a combination of terminations and layoffs, and KV expects to recall some employees when production and shipment of its products resumes.

KV, which manufactures branded drugs under the Ther-Rx name and generics through its Ethex line, suspended manufacturing and shipping and recalled all products it manufactures late last month, and said that the financial impact could jeopardize a $30 million line of credit.

In July, FDA and the US Marshals Service seized $24.2 million worth of unapproved new drugs from the company following an inspection of several plants by the agency, which found it in violation of an FDA enforcement notice and manufacturing unapproved new drugs including treatments for cough, cold, topical wounds, skin bleaching and gastrointestinal conditions, as well as narcotic drugs products.   
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...